Cradle, an AI biotech company based in Amsterdam and Zurich, has secured $73 million in funding to further develop its AI-driven protein engineering platform. The platform aims to revolutionize planetary health by making biology engineering more accessible and efficient, allowing for the discovery and development of animal-free foods, therapeutics, and sustainable chemicals. The company's unique approach has shown to dramatically reduce the number of experimental rounds needed, resulting in a 12-fold increase in speed compared to traditional methods.

Cradle has already partnered with leading companies like Novo Nordisk and Johnson & Johnson for research and development across various sectors. The company's goal is to empower a million scientists with its software and accelerate the process of protein design in industries such as pharmaceuticals, diagnostics, food, and agriculture. With the support of investors like IVP and Index Ventures, Cradle is poised to lead the way in AI-driven protein engineering and make a significant impact on global health and sustainability.